Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Supernus Pharmaceuticals: Clinical Trials & FDA Approval Profile

Supernus Pharmaceuticals (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (4 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.1%
Median Closed Enrollment vs National (145 pts)69 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Supernus Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)5 (4)
Completed vs Stopped Early10 / 4 (21.1%)
Median Closed Actual Enrollment69 participants
Physical Hospital Site Disclosure52.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Supernus Pharmaceuticals
Hospital Research SiteLocationShared Protocols
The Alfred HospitalMelbourne, Victoria4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Supernus Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresPhase IIRECRUITING
NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyPhase IIRECRUITING
NCT03597503Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentPhase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Supernus Pharmaceuticals Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI